What's Happening?
Gilead Sciences, Inc. has set an ambitious sales target for its new long-acting PrEP injection, Yeztugo, predicting it will achieve $1 billion in revenue in 2026. This projection comes as the company reports a strong launch trajectory for the drug, which
was approved in June 2025. In the first quarter of 2026, Yeztugo generated $166 million, marking a 72% increase from the previous quarter. The drug's accessibility has been a significant factor in its success, with approximately 95% of individuals in the U.S. covered, allowing them to access Yeztugo with no co-pay. Gilead's Chief Commercial Officer, Johanna Mercier, highlighted the positive feedback from healthcare professionals and patients, noting that the ease of access and confidence in the injection have contributed to its uptake. Yeztugo is now the leading long-acting injectable in the switch market, capturing patients transitioning from other PrEP types, as well as those new to HIV prophylaxis.
Why It's Important?
The projected success of Yeztugo underscores Gilead's strategic positioning in the HIV prevention market, which remains a significant revenue driver for the company. With HIV sales reaching $5.03 billion globally in the first quarter, Yeztugo's performance is expected to bolster Gilead's financial growth. The drug's accessibility and positive reception could set a precedent for future long-acting injectables, potentially influencing market dynamics and patient care standards. Additionally, the anticipated approval of Gilead's CAR T therapy, anito-cel, for multiple myeloma, could further enhance the company's portfolio, offering new treatment options and expanding its market reach.
What's Next?
Gilead is preparing for the potential approval and launch of anito-cel, its CAR T therapy for relapsed or refractory multiple myeloma, with a target FDA action date of December 23, 2026. The company is also exploring the use of anito-cel in earlier lines of treatment, including newly diagnosed multiple myeloma and smoldering cases. This strategic expansion could provide important treatment options for patients and strengthen Gilead's position in the oncology market. As Gilead continues to innovate and expand its product offerings, the company is poised to maintain its leadership in the biopharmaceutical industry.
